Literature DB >> 8804571

Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin.

Q A Sang1, M K Bodden, L J Windsor.   

Abstract

Proteolytic and nonproteolytic methods were used to investigate the mechanism(s) by which human fibroblast progelatinase A and fibroblast-type procollagenase can be activated. Both collagenase and matrilysin were able to activate progelatinase A, resulting in an amino terminus in gelatinase A of Tyr81. The cleavage occurred distal to Cys73 within the sequence of PRCGNPDVAN80-Y81NFFPRKP. While several nonproteolytic reagents were tested, only the heavy metal Hg(II) and p-chloromercuribenzoate (PCMB) were able to induce activation of progelatinase A and resulted in the conversion of the latent 72-kDa gelatinase A to an active form of about 64.5 kDa. Matrilysin was also able to activate procollagenase and resulted in an amino terminus in collagenase of Phe81. These results suggest that fibroblast-type collagenase and matrilysin may be physiologically relevant activators of progelatinase A; the maintenance of latency and the process of activation for progelatinase A may occur through the cysteine-switch mechanism, and the proteolytic activation of procollagenase by matrilysin resulted in the same amino terminus as produced by stromelysin-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804571     DOI: 10.1007/bf01887112

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  44 in total

1.  The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation.

Authors:  W G Stetler-Stevenson; H C Krutzsch; M P Wacher; I M Margulies; L A Liotta
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

2.  Monoclonal antibodies to human fibroblast procollagenase. Inhibition of enzymatic activity, affinity purification of the enzyme, and evidence for clustering of epitopes in the NH2-terminal end of the activated enzyme.

Authors:  B Birkedal-Hansen; W G Moore; R E Taylor; A S Bhown; H Birkedal-Hansen
Journal:  Biochemistry       Date:  1988-09-06       Impact factor: 3.162

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.

Authors:  I E Collier; S M Wilhelm; A Z Eisen; B L Marmer; G A Grant; J L Seltzer; A Kronberger; C S He; E A Bauer; G I Goldberg
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

Review 5.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

6.  The activation of human skin fibroblast procollagenase. Sequence identification of the major conversion products.

Authors:  G A Grant; A Z Eisen; B L Marmer; W T Roswit; G I Goldberg
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

7.  An internal cysteine plays a role in the maintenance of the latency of human fibroblast collagenase.

Authors:  L J Windsor; H Birkedal-Hansen; B Birkedal-Hansen; J A Engler
Journal:  Biochemistry       Date:  1991-01-22       Impact factor: 3.162

8.  Human progelatinase A can be activated by matrilysin.

Authors:  T Crabbe; B Smith; J O'Connell; A Docherty
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

9.  Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor.

Authors:  B Lovejoy; A Cleasby; A M Hassell; K Longley; M A Luther; D Weigl; G McGeehan; A B McElroy; D Drewry; M H Lambert
Journal:  Science       Date:  1994-01-21       Impact factor: 47.728

10.  Proteolytic and non-proteolytic activation of human neutrophil progelatinase B.

Authors:  Q X Sang; H Birkedal-Hansen; H E Van Wart
Journal:  Biochim Biophys Acta       Date:  1995-09-06
View more
  8 in total

1.  Computational sequence analysis of matrix metalloproteinases.

Authors:  Q A Sang; D A Douglas
Journal:  J Protein Chem       Date:  1996-02

2.  Potential of Raloxifene in reversing osteoarthritis-like alterations in rat chondrocytes: an in vitro model study.

Authors:  Aysegul Kavas; Seda Tuncay Cagatay; Sreeparna Banerjee; Dilek Keskin; Aysen Tezcaner
Journal:  J Biosci       Date:  2013-03       Impact factor: 1.826

3.  Association of matrix metalloproteinase-7 (-181A>G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir Valley.

Authors:  Manzoor A Malik; Kiran L Sharma; Showket A Zargar; Balraj Mittal
Journal:  Saudi J Gastroenterol       Date:  2011 Sep-Oct       Impact factor: 2.485

4.  MMP7 Polymorphisms - A new tool in molecular pathology to understand esophageal cancer.

Authors:  Prashant P Bavi; Rong Bu; Shahab Uddin; Khawla S Al-Kuraya
Journal:  Saudi J Gastroenterol       Date:  2011 Sep-Oct       Impact factor: 2.485

Review 5.  The regulation of MMP targeting to invadopodia during cancer metastasis.

Authors:  Abitha Jacob; Rytis Prekeris
Journal:  Front Cell Dev Biol       Date:  2015-02-02

Review 6.  Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Cancers (Basel)       Date:  2014-12-30       Impact factor: 6.639

7.  A new synthetic matrix metalloproteinase inhibitor reduces human mesenchymal stem cell adipogenesis.

Authors:  Dale B Bosco; Mark D Roycik; Yonghao Jin; Martin A Schwartz; Ty J Lively; Diego A R Zorio; Qing-Xiang Amy Sang
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

8.  The effects of interleukin-1β in modulating osteoclast-conditioned medium's influence on gelatinases in chondrocytes through mitogen-activated protein kinases.

Authors:  Jing Xie; Na Fu; Lin-Yi Cai; Tao Gong; Guo Li; Qiang Peng; Xiao-Xiao Cai
Journal:  Int J Oral Sci       Date:  2015-12-18       Impact factor: 6.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.